Sagent Pharmaceuticals Announces The Approval Of Zoledronic Acid Injection 4 Mg Per 100 ML In A Premix Bag

SCHAUMBURG, Ill., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the approval of Zoledronic Acid Injection 4 mg per 100 mL, the generic form of the bisphosphonate Zometa®, in a ready-to-use premix IV bag.   According to IMS data for the 12 months ending June 2013, the US market for Zoledronic Acid Injection 4 mg approximated $500 million. As with all products in Sagent's portfolio, Zoledronic Acid Injection features Sagent's PreventIV Measures SM packaging and labeling, designed to help reduce medication errors. 

"Sagent is pleased to announce the approval of Zoledronic Acid Injection 4mg in the enhanced packaging option of a ready-to-use premix bag," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board of Sagent. "We anticipate our premix bag presentation will complement the vial product we launched on March 5."

About Zoledronic Acid Injection 4 mg

Zoledronic Acid Injection 4 mg is indicated for the treatment of hypercalcemia of malignancy, patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.

The package insert, available at www.sagentpharma.com , contains the indications, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.  Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: INVESTOR CONTACT:         Jonathon Singer, Sagent         847-908-1605         jsinger@sagentpharma.com